- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- NGS-MRD, Myeloablative allogeneic HCT with a non-TBI conditioning regimen
- Diagnostic Test · Drug
- Lead sponsor
- Pediatric Transplantation & Cellular Therapy Consortium
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 1,384
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Mixed Phenotype Acute Leukemia
- Interventions
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy, Ipilimumab, Nivolumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Lexington, Kentucky • Baltimore, Maryland + 4 more
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, L3 Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma
- Interventions
- ifosfamide, etoposide, rituximab, carboplatin, filgrastim, methotrexate, cytarabine, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Postherpetic Neuralgia, Pain
- Interventions
- Transdermal/Patch (Bupivacaine TTS [Eladur™])
- Drug
- Lead sponsor
- Durect
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 7
- States / cities
- La Jolla, California • Loma Linda, California • Santa Monica, California + 4 more
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia, Undifferentiated Leukemia, Prolymphocytic Leukemia, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Myelodysplastic Syndrome With Excess Blasts-1, Burkitt Lymphoma, Relapsed T-Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Myeloproliferative Neoplasm, Myelofibrosis
- Interventions
- Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine, Cyclophosphamide, Bone Marrow Cell Transplant, Total Body Irradiation, Sirolimus Pill, Mycophenolate Mofetil
- Biological · Drug · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Herpes Zoster, Shingles
- Interventions
- Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix, Amezosvatein Adjuvant Dose Arm D, Amezosvatein Adjuvant Dose Arm F, Amezosvatein Adjuvant Dose Arm H, Amezosvatein Adjuvant Dose Arm J, Amezosvatein Adjuvant Dose Arm L
- Biological
- Lead sponsor
- Curevo Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,516 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2032
- U.S. locations
- 14
- States / cities
- Tempe, Arizona • Coral Gables, Florida • Tampa, Florida + 11 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Fomivirsen sodium
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 25
- States / cities
- Irvine, California • Los Angeles, California • Pasadena, California + 19 more
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate
- Biological · Drug · Procedure
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, epirubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cytomegalovirus Infections
- Interventions
- maribavir, ganciclovir
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 55
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 42 more
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Foscarnet sodium, Ganciclovir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 9
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 4 more
- Conditions
- Herpes Zoster
- Interventions
- EPB-348, Valacyclovir
- Drug
- Lead sponsor
- Epiphany Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 373 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- CMV, AdV Infection, AdV Reactivation, Adenovirus, Cytomegalovirus Infections
- Interventions
- Standard of Care Antiviral medications, Viral CTLs
- Drug · Biological
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 1 Day to 30 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Valhalla, New York • Milwaukee, Wisconsin
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegaloviral Infection, Hematopoietic and Lymphoid Cell Neoplasm, JC Virus Infection, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
- Interventions
- Virus-specific Cytotoxic T-lymphocytes
- Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Nelfinavir mesylate
- Drug
- Lead sponsor
- Agouron Pharmaceuticals
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 5 more
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Retinitis, Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 10 more
- Conditions
- Encephalitis, Herpes Simplex, Keratitis, Mouth Disease, Skin Disease
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- busulfan, cyclophosphamide, Stem cell infusion, Total body irradiation
- Drug · Biological · Radiation
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2019
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Cytomegalovirus Disease
- Interventions
- Valganciclovir, CMV hyperimmune globulin
- Drug · Biological
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Herpes Zoster, Shingles, Genital Herpes
- Interventions
- Valacyclovir Hydrochloride
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- HIV, HIV Infections
- Interventions
- Valacyclovir, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Measles, Mumps, Rubella, Varicella
- Interventions
- MMR-II, Pro-Quad, Varivax
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Months to 12 Months
- Enrollment
- 105 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cytomegalovirus Infections, HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 23 more